The NODE-202 Study Multi-Center, Multi-National, Open-Label, Efficacy and Safety Study of Etripamil Nasal Spray in Pediatric Patients With Paroxysmal Supraventricular Tachycardia

NODE-202 is a Phase 2, multicenter, multinational, single dose, open-label, 2-part, sequential design study in pediatric patients with an established diagnosis of paroxysmal supraventricular tachycardia (PSVT) presenting with a symptomatic episode of PSVT.
In Part 1, at least 30 patients aged 12 to <18 years will be enrolled and treated with etripamil nasal spray (NS). Efficacy, safety, tolerability and PK (for at least 12 patients) will be assessed after administration of 70 mg etripamil NS (Part 1A). At least 18 subsequent patients will be enrolled and treated with the etripamil NS with the dose determined by the Pharmacokinetic (PK) analysis and will undergo efficacy and safety/tolerability assessments (Part 1B).
In Part 2, at least 30 patients aged 6 to <12 years will be enrolled and treated with etripamil NS at a dose selected based on appropriate body size-based modeling, as well as efficacy, safety/tolerability, and PK data collected in Part 1. Efficacy, safety, tolerability and PK (for at least 12 patients) will be assessed after administration of etripamil NS (Part 2A). At least 18 subsequent patients will be enrolled and treated with the etripamil NS with the dose determined by the PK analysis and will undergo efficacy and safety/tolerability assessments (Part 2B).
The study will include the following visits: A Screening Visit, A Treatment Visit, , and A Follow-Up/End of Study Visit.

开始日期2023-12-11

申办/合作机构

Milestone Pharmaceuticals, Inc.

NCT05511870 / Completed临床1期

A Single Center, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Etripamil in Healthy Chinese Subjects

The objectives of the study are as below:
Primary:
·To evaluate the pharmacokinetics (PK) of Etripamil in healthy adult Chinese subjects
Secondary:
To evaluate the pharmacodynamics (PD) of Etripamil in healthy adult Chinese subjects
To evaluate the safety and tolerability of Etripamil in healthy adult Chinese subjects
Exploratory:
·To evaluate the PK exposure-PD response relationship of etripamil in healthy adult Chinese subjects

开始日期2023-03-07

申办/合作机构

箕星药业科技（上海）有限公司

[+1]

CTR20221959 / Completed临床1期

一项在中国健康受试者中评价Etripamil药代动力学、药效学、安全性和耐受性的单中心、随机、双盲、安慰剂对照1期临床研究

主要目的： · 在中国健康成年受试者中评价Etripamil的药代动力学（PK）次要目的： · 在中国健康成年受试者中评价Etripamil的药效学（PD） · 在中国健康成年受试者中评价Etripamil的安全性和耐受性探索性目的： · 在中国健康成年受试者中评价Etripamil的PK（暴露）-PD（效应）关系

开始日期2023-03-07

申办/合作机构

Milestone Pharmaceuticals, Inc.

[+2]

100 项与艾曲帕米相关的临床结果

登录后查看更多信息

100 项与艾曲帕米相关的转化医学

登录后查看更多信息

100 项与艾曲帕米相关的专利（医药）

登录后查看更多信息

项与艾曲帕米相关的文献（医药）

2024-04-01·American heart journal

Rationale and design of the NODE-303 study: evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings

Article

作者: Stambler, Bruce ; Uribe, Juan Agudelo ; Vyselaar, John ; Camm, A John ; Sears, Samuel F ; Shardonofsky, Silvia ; Noseworthy, Peter A ; Omodele, Sarah ; Bharucha, David B ; Bui, Hanh ; Ip, James E ; Coutu, Benoit ; Parody, Maria Leonor ; Singh, Narendra

BACKGROUND:

Paroxysmal supraventricular tachycardia (PSVT) is a common episodic arrhythmia characterized by unpredictable onset and burdensome symptoms including palpitations, dizziness, chest pain, distress, and shortness of breath. Treatment of acute episodes of PSVT in the clinical setting consists of intravenous adenosine, beta-blockers, and calcium channel blockers (CCBs). Etripamil is an intranasally self-administered L-type CCB in development for acute treatment of AV-nodal dependent PSVT in a nonmedical supervised setting.

METHODS:

This paper summarizes the rationale and study design of NODE-303 that will assess the efficacy and safety of etripamil. In the randomized, double-blinded, placebo-controlled, Phase 3 RAPID trial, etripamil was superior to placebo in the conversion of single PSVT episodes by 30 minutes post initial dose when administered in the nonhealthcare setting; this study required a mandatory and observed test dosing prior to randomization. The primary objective of NODE-303 is to evaluate the safety of symptom-prompted, self-administered etripamil for multiple PSVT episodes in real-world settings, without the need for test dosing prior to first use during PSVT. Secondary endpoints include efficacy and disease burden. Upon perceiving a PSVT episode, the patient applies an electrocardiographic monitor, performs a vagal maneuver, and, if the vagal maneuver is unsuccessful, self-administers etripamil 70 mg, with an optional repeat dose if symptoms do not resolve within 10 minutes after the first dose. A patient may treat up to four PSVT episodes during the study. Adverse events are recorded as treatment-emergent if they occur within 24 hours after the administration of etripamil.

RESULTS:

Efficacy endpoints include time to conversion to sinus rhythm within 30 and 60 minutes after etripamil administration, and the proportion of patients who convert at 3, 5, 10, 20, 30, and 60 minutes. Patient-reported outcomes are captured by the Brief Illness Perception Questionnaire, the Cardiac Anxiety Questionnaire, the Short Form Health Survey 36, the Treatment Satisfaction Questionnaire for Medication and a PSVT survey.

CONCLUSIONS:

Overall, these data will support the development of a potentially paradigm-changing long-term management strategy for recurrent PSVT.

2023-12-01·Circulation. Arrhythmia and electrophysiology

Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201)

Article

作者: Gosselin, Gilbert ; Thermil, Nathalie ; Mondésert, Blandine ; Guertin, Marie-Claude ; Camm, A John ; Kowey, Peter R ; Shardonofsky, Silvia ; Ip, James E ; Dorian, Paul ; Piccini, Jonathan P ; Alings, Marco ; Bharucha, David B ; Prins, Fransisco J ; Al Windy, Nadea ; van Eck, Jwm ; Stambler, Bruce S ; Roy, Denis ; Roux, Jean-Francois

BACKGROUND::

Despite chronic therapies, atrial fibrillation (AF) leads to rapid ventricular rates (RVR) often requiring intravenous treatments. Etripamil is a fast-acting, calcium-channel blocker administered intranasally affecting the atrioventricular node within minutes.

METHODS::

Reduction of Ventricular Rate in Patients with Atrial Fibrillation evaluated the efficacy and safety of etripamil for the reduction of ventricular rate (VR) in patients presenting urgently with AF-RVR (VR ≥110 beats per minute [bpm]), was randomized, double-blind, placebo-controlled, and conducted in Canada and the Netherlands. Patients presenting urgently with AF-RVR were randomized (1:1, etripamil nasal spray 70 mg: placebo nasal spray). The primary objective was to demonstrate the effectiveness of etripamil in reducing VR in AF-RVR within 60 minutes of treatment. Secondary objectives assessed achievement of VR <100 bpm, reduction by ≥10% and ≥20%, relief of symptoms and treatment effectiveness; adverse events; and additional measures to 360 minutes.

RESULTS::

Sixty-nine patients were randomized, 56 dosed with etripamil (n=27) or placebo (n=29). The median age was 65 years; 39% were female patients; proportions of AF types were similar between groups. The difference of mean maximum reductions in VR over 60 minutes, etripamil versus placebo, adjusting for baseline VR, was −29.91 bpm (95% CI, −40.31 to −19.52; P <0.0001). VR reductions persisted up to 150 minutes. Significantly greater proportions of patients receiving etripamil achieved VR reductions <100 bpm (with longer median duration <100 bpm), or VR reduction by ≥10% or ≥20%, versus placebo. VR reduction ≥20% occurred in 66.7% of patients in the etripamil arm and no patients in placebo. Using the Treatment Satisfaction Questionnaire for Medication-9, there was significant improvement in satisfaction on symptom relief and treatment effectiveness with etripamil versus placebo. Serious adverse events were rare; 1 patient in the etripamil arm experienced transient severe bradycardia and syncope, assessed as due to hypervagotonia.

CONCLUSIONS::

Intranasal etripamil 70 mg reduced VR and improved symptom relief and treatment satisfaction. These data support further development of self-administered etripamil for the treatment of AF-RVR.

REGISTRATION::

URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT04467905

2023-12-01·Cardiology and therapy

Podcast on Self-administered Intranasal Etripamil for Symptomatic Paroxysmal Supraventricular Tachycardia: The RAPID Trial

Letter

作者: Stambler, Bruce S ; Ip, James E

Paroxysmal supraventricular tachycardia (PSVT) is commonly seen in clinical practice and represents a significant burden to the healthcare system and to patients. First-line treatments include calcium channel blockers (CCB), although they are intravenous and require medical supervision. Etripamil is an investigational self-administered intranasal L-type CCB for unsupervised treatment of PSVT. In this podcast, we discuss the RAPID trial (NCT03464019), which was a phase 3 study that evaluated the safety and efficacy of etripamil in terminating PSVT episodes using a repeat-dosing regimen. RAPID was a multicenter, randomized trial that enrolled adults with electrocardiograph (ECG)-documented PSVT episodes lasting ≥ 20 min. Patients who tolerated test doses of etripamil were randomized 1:1 to receive either etripamil or placebo. Upon perceiving PSVT symptoms, patients began ECG monitoring and performed a vagal maneuver. If arrhythmia termination was unsuccessful, they self-administered 70 mg of etripamil or placebo, followed by an optional second dose after 10 min. The primary endpoint was time to conversion of PSVT to sinus rhythm within 30 min of the initial dose and sustained for ≥ 30 s. The safety group included all patients who self-administered the study treatment. Of 692 enrollees, 184 self-administered the study drug (99 etripamil, 85 placebo) for ECG-confirmed PSVT. Conversion of PSVT to sinus rhythm within 30 min was achieved in 64.3% of etripamil-treated subjects versus 31.2% of placebo-treated subjects. A significant threefold reduction in the median time to conversion of 17.2 min was observed in the etripamil group versus 53.5 min in the placebo group. Treatment-emergent adverse events were mild or moderate and primarily included transient nasal discomfort, nasal congestion, and rhinorrhea. If etripamil is approved by the US FDA, it can potentially address a significant unmet need for PSVT treatment outside a clinical setting, reducing the need for intravenous treatments that require medical supervision.Podcast available for this article.

项与艾曲帕米相关的新闻（医药）

2024-09-04

·GlobeNewswire-Health Care

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors (“Board”), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings broad commercial experience and proven capabilities of advancing innovative products aimed at significantly enhancing patients’ lives. “Joe is an accomplished leader with a track record of driving growth, and we are thrilled to welcome him to our Board,” said Robert J. Wills, PhD, Chairman of the Board of Milestone. “His tremendous experience across an extensive range of biopharmaceutical companies and products provides a skillset that is an excellent complement to the existing board. We look forward to his strategic guidance as we prepare for potential approval of our investigational drug CARDAMYST™ (etripamil nasal spray) for paroxysmal supraventricular tachycardia.” Mr. Papa commented, “I am very impressed by Milestone’s leadership team, culture of innovation, and commitment to improving the lives of people with life-altering heart conditions. I see a great opportunity for value creation and look forward to collaborating with the Board and the team to advance CARDAMYST and, if approved, to help bring this much needed treatment to patients.” About Joseph Papa Joseph Papa has over 35 years of experience in the pharmaceutical, healthcare and specialty pharmaceutical industries. Since February 2024, he has served as Chief Executive Officer of Emergent BioSolutions (NYSE: EBS). He served as Chief Executive Officer of Bausch + Lomb Corporation from May 2022 to March 2023 to facilitate a smooth leadership transition. Previously, Mr. Papa served as Chairman and CEO of Bausch Health from 2016 to 2022, where he oversaw the company’s rapid growth and spin-off of Bausch + Lomb. From 2006 to 2016, Mr. Papa served as Chairman and CEO of Perrigo. Prior to Perrigo, Mr. Papa served as President of PTS for Cardinal Health, President of Watson Pharmaceuticals, President of U.S. operations for Searle/Pharmacia, Chief Operating Officer of DuPont Pharmaceuticals and Vice President of Marketing for Novartis. He currently serves as Chair of the board of directors of SparingVision, a privately held genomic medicines company, and as a member of the board of directors of Candel Therapeutics (Nasdaq: CADL), a clinical stage biopharmaceutical company developing immunotherapies for cancer patients, where he chairs the compensation committee. He previously served on the boards of directors of Prometheus Biosciences, as lead independent director and chair of the compensation committee until the company’s sale to Merck in 2023, and Smith & Nephew plc as chair of the remuneration committee. Mr. Papa holds a B.S. in pharmacy from the University of Connecticut and an M.B.A. from Northwestern University’s Kellogg Graduate School of Management. About Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone’s lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR. Forward-Looking Statements This press release contains forward-looking statements and forward looking information within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws (“forward looking statements”). Words such as “believe,” “continue,” “could,” “demonstrate,” “designed,” “develop,” “estimate,” “expect,” “may,” “pending,” “plan,” “potential,” “progress,” “will”, “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the timing of upcoming clinical trial milestones and related data; the timing of the FDA’s review of the NDA and the FDA’s potential approval of CARDAMYST; the potential of etripamil to help patients living with these serious heart arrythmias; and the timing of the launch of etripamil. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, whether our future interactions with the FDA will have satisfactory outcomes; whether and when, if at all, our NDA for etripamil will be approved by the FDA; whether the FDA will require additional trials or data which may significantly delay and put at risk our efforts to obtain approval and may not be successful, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, Russian hostilities in Ukraine and ongoing disputes in Israel and Gaza and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone’s capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone’s filings with the U.S. Securities and Exchange Commission (SEC) and the Canadian securities regulatory authorities, including in its annual report on Form 10-K for the year ended December 31, 2024, under the caption “Risk Factors,” as such discussion may be updated from time to time by subsequent filings Milestone may make with the SEC and the Canadian securities regulatory authorities, which is available under Milestone’s profile on EDGAR at www.sec.gov and on SEDAR at www.sedarplus.ca. Except as required by applicable law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available or based on future events or otherwise. Contact:Kim Fox, Vice President, Communications, kfox@milestonepharma.com Investor RelationsChris Calabrese, ccalabrese@lifesciadvisors.com Kevin Gardner, kgardner@lifesciadvisors.com

高管变更

2024-09-03

·GlobeNewswire-Health Care

Milestone® Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

MONTREAL and CHARLOTTE, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, to take place from September 9-11, 2024, in New York City. The Fireside Chat will be on September 10th at 2 PM EDT. The webcast is available to watch both live and replay for approximately 90 days following the presentation in the News & Events section of Milestone's website www.milestonepharma.com. About Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone’s lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR. Contact:Kim Fox, Vice President, Communications,kfox@milestonepharma.com Investor RelationsChris Calabrese,ccalabrese@lifesciadvisors.com Kevin Gardner,kgardner@lifesciadvisors.com

2024-08-26

·GlobeNewswire-Health Care

Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024

MONTREAL and CHARLOTTE, N.C., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced an upcoming data presentation on etripamil at the annual meeting of the European Society of Cardiology, ESC Congress 2024 in London, United Kingdom on August 30, 2024. Professor John Camm will present patient reported outcomes data from the NODE-303 Phase 3 trial of etripamil in paroxysmal supraventricular tachycardia (PSVT) in a moderated poster presentation. The poster presentation will be available following the embargo at: https://MilestonePharma.com. “We look forward to Professor Camm’s upcoming presentation at the ESC Congress 2024 on this important topic of PSVT and the self-administration of investigational etripamil nasal spray in a medically unsupervised setting,” said David Bharucha, MD, PhD, FACC, Chief Medical Officer, Milestone Pharmaceuticals. “These patient-reported outcomes data, that will be presented, provide insights about patient experience, satisfaction, and disease management.” ESC Presentation Details: Moderated Poster Presentation Title:Quality of Life Measures with Etripamil Self-Administration for Acute Episodes of Paroxysmal Supraventricular Tachycardia in a Medically Unsupervised Setting: Patient-Reported Outcomes from NODE-303 Presenter: John Camm, MD, Professor of Clinical Cardiology, St. George's University of London, United Kingdom Date and time:Friday, August 30, 2024, 13:00 – 13:50 BST About Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR. Contact:Kim Fox, Vice President, Communications,kfox@milestonepharma.com Investor RelationsChris Calabrese,ccalabrese@lifesciadvisors.com Kevin Gardner,kgardner@lifesciadvisors.com

临床3期

100 项与艾曲帕米相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10932	-	-	DB12605

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阵发性室上性心动过速	申请上市	美国	Milestone Pharmaceuticals, Inc.	2024-02-26
室上性心动过速	临床3期	中国	箕星药业科技（上海）有限公司	2022-06-30
室上性心动过速	临床3期	中国	Milestone Pharmaceuticals, Inc.	2022-06-30
心房颤动	临床2期	美国	Milestone Pharmaceuticals, Inc.	2020-10-30
心房颤动	临床2期	加拿大	Milestone Pharmaceuticals, Inc.	2020-10-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03464019 (NODE-301 \| RAPID, CTgov)	临床3期	阵发性室上性心动过速	1,097	Placebo (Part 1 - Placebo Single Dose)	遞製獵範獵繭鹹鹽壓積(顧範夢憲糧蓋願淵鹽簾) = 憲鏇艱繭壓鑰網蓋鑰壓衊顧積醖淵窪顧糧顧築 (範範襯遞鏇衊衊膚顧齋, 選齋蓋齋廠鹹齋壓鹹築 ~ 糧齋製網構願繭顧窪夢) 更多	-	2024-07-12
				Etripamil (Part 1 - Etripamil 70 mg)	遞製獵範獵繭鹹鹽壓積(顧範夢憲糧蓋願淵鹽簾) = 窪築築鏇廠襯觸積築醖衊顧積醖淵窪顧糧顧築 (範範襯遞鏇衊衊膚顧齋, 鹽網築簾憲築選鏇憲簾 ~ 範壓艱積夢膚製範襯艱) 更多
NCT04072835 (NODE-303, CTgov)	临床3期	阵发性室上性心动过速	1,116	etripamil NS	蓋襯醖遞鹹鏇衊夢膚網(鏇夢憲範網獵網蓋廠窪) = 獵鹹蓋獵鹹醖醖醖蓋鑰淵遞窪構獵襯餘選觸鏇 (願餘製壓簾築衊構鏇鹹, 網製繭醖網膚糧範積廠 ~ 製窪壓憲遞膚鹽壓鑰蓋) 更多	-	2024-05-23
NCT04467905 (ReVeRA-201, Pubmed \| Circ Arrhythm Electrophysiol)	临床2期	心房颤动	-	Etripamil nasal spray 70 mg	憲範鏇積膚憲糧廠憲糧(鬱鏇築壓簾選襯窪壓繭) = 1 patient in the etripamil arm experienced transient severe bradycardia and syncope, assessed as due to hypervagotonia 築選範範糧膚壓蓋範製 (壓遞餘鏇鹽衊鑰選鹹繭 ) 更多	积极	2023-12-01
NCT03464019 (RAPID, Pubmed)	临床3期	房室结折返性心动过速	692	Etripamil 70 mg nasal spray	蓋鏇遞艱網網鬱顧憲衊(膚窪範觸願襯糧夢簾廠) = Adverse events occurring in at least 5% of patients treated with etripamil were nasal discomfort (23%), nasal congestion (13%), and rhinorrhea (9%) 遞廠夢積簾顧鹹鏇製糧 (築憲淵齋鹹構鹹築選醖 ) 更多	积极	2023-06-15
				Placebo
NCT03635996 (CTgov)	临床3期	阵发性室上性心动过速	169	Aptar Pharma Nasal Spray Bidose System+Etripamil NS 70 mg	繭鬱範獵顧鏇範鏇憲顧(齋衊夢鑰醖鬱醖選鑰鹹) = 觸襯廠鬱廠醖選鹽壓憲糧齋繭獵繭範鬱襯鹹鏇 (獵製壓範鹹構選齋窪網, 壓夢顧艱淵醖觸襯淵壓 ~ 衊蓋廠範餘顧壓壓積顧) 更多	-	2023-04-24
NCT03464019 (NODE-301, Pubmed) 人工标引	临床3期	阵发性室上性心动过速	156	Etripamil	鏇糧築齋遞壓顧衊觸齋(鏇夢糧構壓窪鏇繭窪網): HR = 1.086 (95% CI, 0.726 ~ 1.623), P-Value = 0.12	不佳	2022-11-28
				Placebo
NCT03464019 (RAPID, Corporate Publications) 人工标引	临床3期	阵发性室上性心动过速	706	Etripamil	艱製積淵鏇膚簾膚膚願(壓簾鏇鹽淵獵糧淵鹽築) = 顧鏇醖獵壓繭淵廠壓糧簾網鏇範築蓋觸襯範鑰 (醖糧繭選艱選壓糧鑰艱 ) 更多	积极	2022-10-17
				Placebo	艱製積淵鏇膚簾膚膚願(壓簾鏇鹽淵獵糧淵鹽築) = 壓獵壓齋醖簾餘襯鑰選簾網鏇範築蓋觸襯範鑰 (醖糧繭選艱選壓糧鑰艱 ) 更多
NCT02296190 (NODE-1, CTgov)	临床2期	阵发性室上性心动过速	199	Placebo	鏇構鏇網鹽壓憲艱齋顧(餘繭鏇築鹽廠構鹹製鹹) = 鬱蓋獵窪鹹選鬱夢選廠壓憲鬱鹽蓋築廠選膚築 (齋願壓繭淵憲夢憲網糧, 廠鑰顧範餘衊積餘鹽艱 ~ 築網築窪衊蓋壓獵鬱齋) 更多	-	2020-12-30
NCT03464019 (NODE-301, Corporate Publications) 人工标引	临床3期	阵发性室上性心动过速	431	Etripamil	範蓋製積淵餘鏇襯衊淵(選壓醖窪鹽願淵顧壓顧) = 廠窪蓋夢醖醖齋選鹹襯簾淵醖鑰衊獵蓋獵醖顧 (願簾壓築鏇窪範齋願鹽, 16 ~ 43) 更多	不佳	2020-03-23
				Placebo	範蓋製積淵餘鏇襯衊淵(選壓醖窪鹽願淵顧壓顧) = 網範範製糧製鑰鏇糧憲簾淵醖鑰衊獵蓋獵醖顧 (願簾壓築鏇窪範齋願鹽, 31 ~ 101) 更多
NCT02296190 (NODE-1, Pubmed) 人工标引	临床2期	室上性心动过速	104	MSP-2017	觸鏇製願製淵獵選繭夢(獵鹹遞築鑰夢膚網憲積) = 艱鏇構鑰衊繭積積膚襯獵鹽蓋廠網鑰觸顧遞獵 (夢願積廠艱窪鹹網築艱 )	积极	2018-07-31
				Placebo	觸鏇製願製淵獵選繭夢(獵鹹遞築鑰夢膚網憲積) = 積繭積窪壓構願鏇願糧獵鹽蓋廠網鑰觸顧遞獵 (夢願積廠艱窪鹹網築艱 )